|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...5455565758596061626364...39323933» |
- | ubamatamab (REGN4018) / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron
Trial primary completion date, Combination therapy: Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies (clinicaltrials.gov) - Aug 21, 2024
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2026 --> Jul 2028
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, IO biomarker: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma (clinicaltrials.gov) - Aug 21, 2024
P1, N=40, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Jul 2026 --> Jul 2028 Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
- | Rituxan (rituximab) / Roche
Journal, IO biomarker: Autoimmune Neurobeachin Cerebellar Ataxia. (Pubmed Central) - Aug 21, 2024
Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2025 Neurobeachin-IgG is a new neural antibody biomarker of cerebellar ataxia among a growing antibody repertoire, collectively common but often individually rare.
- | Tyvyt (sintilimab) / Eli Lilly
Trial completion date, Trial termination, Trial primary completion date, Metastases: Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study (clinicaltrials.gov) - Aug 21, 2024
P2, N=6, Terminated, Sponsor: M.D. Anderson Cancer Center
Neurobeachin-IgG is a new neural antibody biomarker of cerebellar ataxia among a growing antibody repertoire, collectively common but often individually rare. Trial completion date: Jul 2026 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2026 --> Feb 2024; All subjects have finished their final visits and follow-up,
- | Aliqopa (copanlisib) / Bayer, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: FIL_Copa-RB: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Aug 21, 2024
P2, N=37, Active, not recruiting, Sponsor: Fondazione Italiana Linfomi - ETS
Trial completion date: Jul 2026 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2026 --> Feb 2024; All subjects have finished their final visits and follow-up, Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
- | Jemperli (dostarlimab-gxly) / GSK
Trial completion date, Trial primary completion date: STARKAP: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma (clinicaltrials.gov) - Aug 21, 2024
P1, N=20, Recruiting, Sponsor: Imperial College London
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024 Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: May 2024 --> Apr 2026
- | zalifrelimab (UGN-301) / Agenus, UroGen, balstilimab (AGEN2034) / Agenus
Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition, Checkpoint block: rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG (clinicaltrials.gov) - Aug 21, 2024
P1, N=36, Recruiting, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: May 2024 --> Apr 2026 Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
- |||||||||| rilvegostomig (AZD2936) / AstraZeneca, datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
New P3 trial, Combination therapy, Monotherapy, Circulating tumor DNA: TROPION-Lung12: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (clinicaltrials.gov) - Aug 21, 2024
P3, N=660, Not yet recruiting, Sponsor: AstraZeneca
- | Bavencio (avelumab) / EMD Serono
Journal, PD(L)-1 Biomarker, IO biomarker, Circulating tumor DNA, Metastases: Profound ctDNA and radiological responses after 2 cycles of avelumab in a metastatic Merkel cell carcinoma of the head and neck. (Pubmed Central) - Aug 20, 2024
Avelumab may achieve rapid and major responses in metastatic MCC. Our study demonstrates that ctDNA mirrors radiological responses and may serve as an ideal companion for diagnosis and disease monitoring in MCC.
- | Ocrevus (ocrelizumab) / Roche
Journal, Real-world evidence, Real-world: Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric study. (Pubmed Central) - Aug 20, 2024
Our study demonstrates that ctDNA mirrors radiological responses and may serve as an ideal companion for diagnosis and disease monitoring in MCC. Our real-world data support the use of ocrelizumab in a much broader pwPPMS population than in the original randomized controlled trial.
- | Rituxan (rituximab) / Roche
Journal: Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM). (Pubmed Central) - Aug 20, 2024
P=N/A
Treatment failure rates were higher for AZA and MMF than RTX in Argentinean NMOSD patients in a real-world setting. High-efficacy treatment increases the opportunity to prevent attacks of NMOSD.
- | Rituxan (rituximab) / Roche
Journal: Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients. (Pubmed Central) - Aug 20, 2024
Despite this, the cumulative percentage of patients hospitalized with COVID-19 disease throughout the observation period of 22 months was low, and no patients required ICU treatment. The results support that vaccinated MS-patients treated with rituximab have a protective effect against serious Covid-19 infection.
- | Promacta (eltrombopag) / Novartis
Journal: Identification of Potential Inhibitors for Drug Resistance in Acute Lymphoblastic Leukemia through Differentially Expressed Gene Analysis and In Silico Screening. (Pubmed Central) - Aug 20, 2024
Our aim is to determine differentially expressed genes (DEGs) related to Asparaginase, Daunorubicin, Prednisolone, and Vincristine resistance and identify potential inhibitors via docking...Following ADMET analysis, three drugs emerged as potential inhibitors: Flunarizine, Talniflumate, and Eltrombopag...This study promotes a further understanding of drug resistance in ALL, introducing novel genes for consideration in diagnostic screening. It also presents potential inhibitor candidates to tackle drug resistance through repurposing.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Retrospective data, Journal: Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study. (Pubmed Central) - Aug 20, 2024
Although no significant difference was observed for OS and PFS, the ORR of patients in the HAIC group after the failure of atezo-bev therapy was superior to that of newly diagnosed patients. HAIC may prolong survival in patients with HCC after atezo-bev treatment failure.
- | Rituxan (rituximab) / Roche
Retrospective data, Journal: Rituximab as Treatment for Lupus Nephritis: Data From the Peruvian ALMENARA Lupus Cohort. (Pubmed Central) - Aug 20, 2024
CR and responder status were reached in less than one third of LN patients treated with RTX, regardless of the criteria used to define them. However, serum creatinine levels did not increase, and there was a decrease in proteinuria levels during the follow-up.
- | Opdivo (nivolumab) / BMS
Journal, Checkpoint inhibition: Adjuvant immune checkpoint inhibitor therapy may benefit pediatric patients with stage III melanoma and sentinel lymph node positivity: a case series. (Pubmed Central) - Aug 20, 2024
All patients whose initial therapy included nivolumab in addition to wide local excision did not have recurrence or progression of their disease. This case series highlights trends in the presentation, treatment, and outcomes of pediatric melanoma; however, additional multi-center studies are needed to establish the clinical utility of such features in pediatric melanoma.
- | Monjuvi (tafasitamab-cxix) / Incyte
Journal, CAR T-Cell Therapy: Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells. (Pubmed Central) - Aug 20, 2024
The bORR, bCRR, 6-month PFS and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1% and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatments improved outcomes of patients who relapsed after CAR T-cell.
- | Rituxan (rituximab) / Roche
Journal: Sialadenitis in Antineutrophil Cytoplasmic Antibodies Vasculitis. (Pubmed Central) - Aug 20, 2024
Easy accessibility of salivary glands allows early biopsy and timely treatment. In our case with GPA, salivary gland involvement was unresponsive to cyclophosphamide but remitted with rituximab.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Review, Journal, Combination therapy, Surgery: Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review. (Pubmed Central) - Aug 20, 2024
Subsequently, we confirmed that there was no pathological metastatic lesion in the resected lymph node. Our case is the first report of successful application of the radical therapy to lymph node metastasis of HCC via combination therapy with atezolizumab/bevacizumab.
- ||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Opdivo (nivolumab) / BMS
Clinical, P3 data, Journal, Metastases: Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 (Pubmed Central) - Aug 20, 2024
P2/3
Our case is the first report of successful application of the radical therapy to lymph node metastasis of HCC via combination therapy with atezolizumab/bevacizumab. This 3-year follow-up of ATTRACTION-4 confirmed the long-term clinical benefit and manageable safety of nivolumab?+?chemotherapy in patients with previously untreated advanced gastric cancer.
- | Kisqali (ribociclib) / Novartis
Journal: Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1? Secretion and T Cell Adjuvanticity. (Pubmed Central) - Aug 20, 2024
Furthermore, the liposomes were coadministered with a tumor antigen and used in a therapeutic cancer vaccine, where they facilitated rejection of E.G7-OVA tumors. While further chemical optimization of the ribociclib scaffold is needed, this study provides proof-of-concept for its use as an IL-1 producing adjuvant in various immunotherapeutic contexts.
- | M1069 / EMD Serono, Domain Therap
Preclinical, Journal: Dual A2A/ A2B adenosine receptor antagonist M1069 counteracts immuno-suppressive mechanisms of adenosine and reduces tumor growth in vivo. (Pubmed Central) - Aug 20, 2024
In vivo, M1069 decreased tumor growth as a monotherapy and enhanced anti-tumor activity of bintrafusp alfa (BA) or cisplatin in syngeneic adenosinehi/CD73hi 4T1 breast tumor model, but not in the CD73 knockout (KO) 4T1 tumor model or in adenosinelow/CD73low MC38 murine colon carcinoma model. In summary, our dual A2A/A2B AR antagonist M1069 may counteract immune-suppressive mechanisms of high concentrations of adenosine in vitro and in vivo and enhance the anti-tumor activity of other agents, including BA and cisplatin.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Pembrolizumab-induced hypertrophic lichenoid dermatitis with involvement of an old tattoo. (Pubmed Central) - Aug 20, 2024
In summary, our dual A2A/A2B AR antagonist M1069 may counteract immune-suppressive mechanisms of high concentrations of adenosine in vitro and in vivo and enhance the anti-tumor activity of other agents, including BA and cisplatin. No abstract available
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical, Retrospective data, Review, Journal: Comparative Efficacy and Safety of Immunotherapy on Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Aug 20, 2024
Inconsistency tests were not performed because of the scarcity of direct comparison. Besides, high heterogeneity was observed in our NMA.
- || varlilumab (CDX 1127) / Celldex, Tecentriq (atezolizumab) / Roche
P1 data, Journal, Combination therapy, Metastases: A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC. (Pubmed Central) - Aug 20, 2024
P1
Varlilumab in combination with atezolizumab and RT was safe and well tolerated; no additional signal was identified for toxicity. Clinical activity for the combination was modest with 25% of patients with stable disease as the best response.
- | Rituxan (rituximab) / Roche
Journal: Antineutrophil Cytoplasmic Antibody Vasculitis after Coronary Artery Bypass Grafting. (Pubmed Central) - Aug 20, 2024
Renal biopsy ultimately showed focal necrotizing and crescentic glomerulonephritis, and the patient was successfully managed with corticosteroids and outpatient rituximab. This rare case highlights the importance of having an expanded differential for uncommon causes of cardiovascular disease and unexpected outcomes after coronary artery bypass grafting.
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Retrospective data, Review, Journal, Metastases: Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis. (Pubmed Central) - Aug 20, 2024
The use of CDK4/6 inhibitors in treatment-naive patients with HR + advanced breast cancer significantly improves survival, but also increases the risk of adverse events. Abemaciclib and ribociclib may be the best options for prolonging PFS and OS in treatment-na
- | Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report. (Pubmed Central) - Aug 20, 2024
The patient obtained an 11.7-month-sustained remission period, and he also enjoyed a better quality of life. This case demonstrates that sintilimab plus anlotinib may be a feasible treatment regimen for osteosarcoma patients.
- || Rituxan (rituximab) / Roche
Review, Journal: Atypical presentation of Felty syndrome: Successful management with rituximab therapy-A case report and review of literature. (Pubmed Central) - Aug 20, 2024
Timely diagnosis of neutropenia and splenomegaly in patients with rheumatoid arthritis without joint symptoms is crucial for a better prognosis. Despite the rarity of the condition, clinicians should have a high index of suspicion, and multidisciplinary collaboration between rheumatology, hematology, and other specialists is required for accurate diagnosis.
- | Rituxan (rituximab) / Roche
Journal: Concomitant manifestations of systemic lupus erythematosus flare-up and nodal marginal zone B-cell lymphoma in a 41-year-old male patient: A challenging case report. (Pubmed Central) - Aug 20, 2024
The initial case of SLE flare-up, with concomitant NMZL is being reported as the final diagnosis. In simpler terms, it is possible for lymphoma to manifest as a potential cause of SLE flare-ups, and clinicians should be mindful that they need to consider malignant conditions when faced with treatment resistance.
- || Gazyva (obinutuzumab) / Roche, Biogen
P1/2 data, Journal, Combination therapy: Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase (Pubmed Central) - Aug 20, 2024
P1/2
Future randomised trials comparing this regime to rituximab and lenalidomide are warranted. Genentech and an MD Anderson Core grant.
- | Opdivo (nivolumab) / BMS
Journal, Residual disease, FDG PET: Can FDG-PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non-small cell lung cancer? (Pubmed Central) - Aug 20, 2024
On the other hand, Case 3 showed a tumour response before surgery (PR per RECIST), however, the tumour, maintained FDG uptake (19.5???15.1), and the resected tumour remained residual cells (RVT, 15%). Thus, reduction of FDG uptake on FDG-PET can predict the pathological response to neoadjuvant therapy with nivolumab.
- || Adcetris (brentuximab vedotin) / Takeda, Pfizer
Review, Journal: Insights into uveitis from Brentuximab vedotin in refractory Hodgkin's lymphoma: a case report and brief review. (Pubmed Central) - Aug 20, 2024
Potential mechanisms include BV targeting CD30+ T cells in the uveal tissue or an immune response triggered by the microtubule-disrupting agent MMAE within BV. This highlights the need for vigilant monitoring of ocular adverse events in BV-treated patients and further research into their mechanisms and management.
- | Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Evolving approaches in advanced gallbladder cancer with complete pathological response using chemo?immunotherapy: A case report. (Pubmed Central) - Aug 20, 2024
TOPAZ-1 and KEYNOTE-966 have demonstrated the efficacy of combining immunotherapy (durvalumab and pembrolizumab) with chemotherapy, even in gallbladder cancer (GBC), with a complete response rate of 2.7% in the TOPAZ-1 trial...The patient started chemo-immunotherapy with cisplatin-gemcitabine plus durvalumab in June 2022...Overall, chemo-immunotherapy has been effective in treating metastatic CCA, especially when tailored to specific molecular profiles. These treatments may lead to complete responses and novel strategies.
- || metformin / Generic mfg.
Review, Journal: Unveiling the Protective Role of Metformin against Chemotherapyinduced Cardiotoxicity: A Comprehensive Scoping Review on Nonclinical Studies. (Pubmed Central) - Aug 20, 2024
Further studies are necessary to determine the specifics of this interaction. Still, the promising results of this review suggest that metformin may be an essential tool in the fight against chemotherapy-induced cardiotoxicity.
- || Keytruda (pembrolizumab) / Merck (MSD), Rituxan (rituximab) / Roche
P2 data, Journal: PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenstr (Pubmed Central) - Aug 20, 2024
Treatment was well tolerated, with minimal numbers of immune-mediated AEs typically seen with checkpoint inhibitors. PembroWM is the first study to evaluate the feasibility of PD-1 axis modulation in WM and has shown that in combination with Rituximab the combination is safe and deliverable.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2/3 trial: Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (clinicaltrials.gov) - Aug 20, 2024
P2/3, N=96, Not yet recruiting, Sponsor: Children's Cancer Group, China
- | Brukinsa (zanubrutinib) / BeiGene, Lunsumio (mosunetuzumab-axgb) / Roche
New P2 trial: A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma (clinicaltrials.gov) - Aug 20, 2024
P2, N=36, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin (clinicaltrials.gov) - Aug 20, 2024
P=N/A, N=50, Recruiting, Sponsor: Takeda
PembroWM is the first study to evaluate the feasibility of PD-1 axis modulation in WM and has shown that in combination with Rituximab the combination is safe and deliverable. Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) (clinicaltrials.gov) - Aug 20, 2024
P=N/A, N=28, Recruiting, Sponsor: Fujian Provincial Hospital
- | Tevimbra (tislelizumab-jsgr) / BeiGene
New trial, Metastases: SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 20, 2024
P=N/A, N=2, Recruiting, Sponsor: Cell Origin Biotech (Hangzhou) Co., Ltd.
- |||| Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
New P2 trial: ZEBRA: Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM (clinicaltrials.gov) - Aug 20, 2024
P2, N=55, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Orencia (abatacept) / BMS
Enrollment open: ABAGART: Abatacept for the Treatment of Giant Cell Arteritis (clinicaltrials.gov) - Aug 20, 2024
P3, N=78, Recruiting, Sponsor: University of Pennsylvania
Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 Active, not recruiting --> Recruiting
- | certepetide (LSTA1) / Lisata Therap
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Surgery: Intraperitoneal LSTA1 in CRS-HIPEC (clinicaltrials.gov) - Aug 20, 2024
P1, N=0, Withdrawn, Sponsor: University of California, San Diego
Active, not recruiting --> Recruiting N=21 --> 0 | Trial completion date: Dec 2029 --> Jun 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2028 --> Jun 2024
- Tyvyt (sintilimab) / Eli Lilly
Efficacy and Safety of Sintilimab in Patients With Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis (Exhibit Hall) - Aug 20, 2024 - Abstract #ACG2024ACG_5556;
- Keytruda (pembrolizumab) / Merck (MSD)
Immune Checkpoint Inhibitor (Pembrolizumab) and HSV Hepatitis: A Complex Case in an Immunocompromised Patient (Exhibit Hall) - Aug 20, 2024 - Abstract #ACG2024ACG_5355;
- Keytruda (pembrolizumab) / Merck (MSD)
The Pesky Problem with Pembrolizumab: A Case of Chronic Hepatitis B Reactivation After Use of a Checkpoint Inhibitor (Exhibit Hall) - Aug 20, 2024 - Abstract #ACG2024ACG_5324;
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab-Induced Acute Liver Failure in a Patient With Stage IV Recurrent Uterine Cancer (Exhibit Hall) - Aug 20, 2024 - Abstract #ACG2024ACG_5304;
- Opdivo (nivolumab) / BMS
Effective Management of Advanced Hepatocellular Carcinoma With Nivolumab: A Case Report (Exhibit Hall) - Aug 20, 2024 - Abstract #ACG2024ACG_5234;
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab Associated Acute Esophageal Necrosis (Exhibit Hall) - Aug 20, 2024 - Abstract #ACG2024ACG_4506;